Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Personalized medicine trial expanded to patients with breast, ovarian cancers
October 20th, 2005
ChemGenex Pharmaceuticals Limited (CXSP, CXS) announced that the phase II clinical trial of its investigational anticancer drug, Quinamed (amonafide dihydrochloride) has been expanded to include patients with breast and ovarian cancer. CEO of ChemGenex Pharmaceuticals, Greg Collier, PhD, said the phase II trial was expanded beyond prostate cancer as planned based on results from earlier clinical studies, clinical advice and to provide the company with a broader range of target indications to choose from for the phase III product registration trial. "In the phase I study, which included 32 patients, meaningful responses to Quinamed therapy were...
Source: Women's Health Weekly (2005-10-20)
|
